Shuyan Wan
About
In The Last Decade
Shuyan Wan
12 papers receiving 1.0k citations
Hit Papers
Peers
Comparison fields: 5 of 64
- Hepatology 831
- Epidemiology 674
- Infectious Diseases 277
- Molecular Biology 113
- Pulmonary and Respiratory Medicine 108
Countries citing papers authored by Shuyan Wan
This map shows the geographic impact of Shuyan Wan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuyan Wan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuyan Wan more than expected).
Fields of papers citing papers by Shuyan Wan
This network shows the impact of papers produced by Shuyan Wan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuyan Wan. The network helps show where Shuyan Wan may publish in the future.
Co-authorship network of co-authors of Shuyan Wan
This figure shows the co-authorship network connecting the top 25 collaborators of Shuyan Wan. A scholar is included among the top collaborators of Shuyan Wan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuyan Wan. Shuyan Wan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 7 | |
| 3 | 4 | |
| 4 | 86 | |
| 5 | 1 | |
| 6 | 16 | |
| 7 | 7 | |
| 8 | Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study breakdown → | 477 |
| 9 | Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection breakdown → | 386 |
| 10 | 78 | |
| 11 | 1 | |
| 12 | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.